Medical genetics company Invitae (NVTA), which received backing from SoftBank Group (SFTBY) at the height of the pandemic, has hired restructuring advisers FTI Consulting and law firm Kirkland & Ellis to explore strategic options, including bankruptcy, to address $1.5B in debt, people familiar with the matter told The Wall Street Journal’s Soma Biswas. The company is preparing to file for bankruptcy within weeks, the report said.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on NVTA:
- Invitae partners with BridgeBio for discovery of rare disease therapeutics
- Invitae expects $4M in charges in Q1 from workforce reduction
- Invitae Announces Sale of Reproductive Health Assets
- Invitae Announces Workforce Reduction to Slash Expenses
- Invitae Announces Successful Completion of Asset Acquisition